Atea Pharmaceuticals, Inc.AVIRNASDAQ
Loading
R&D Expenses Over TimeStrong
Percentile Rank86
3Y CAGR+18.6%
5Y CAGR+31.2%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+18.6%/yr
vs +91.0%/yr prior
5Y CAGR
+31.2%/yr
Recent deceleration
Acceleration
-72.4pp
Decelerating
Percentile
P86
Within normal range
vs 5Y Ago
3.9x
Strong expansion
Streak
3 yr
Consecutive growthStrong
PeriodValueYoY Change
2025$148.02M+1.8%
2024$145.40M+9.5%
2023$132.84M+49.5%
2022$88.84M-46.9%
2021$167.21M+339.7%
2020$38.02M+273.9%
2019$10.17M+52.4%
2018$6.67M-